LEADER 04751nam  2200613Ia 450 
001 9910779516303321
005 20230721010724.0
010   $a1-60876-726-4
035   $a(CKB)2550000001041251
035   $a(EBL)3018284
035   $a(SSID)ssj0000852872
035   $a(PQKBManifestationID)12365025
035   $a(PQKBTitleCode)TC0000852872
035   $a(PQKBWorkID)10864464
035   $a(PQKB)11206701
035   $a(MiAaPQ)EBC3018284
035   $a(Au-PeEL)EBL3018284
035   $a(CaPaEBR)ebr10660145
035   $a(OCoLC)923657824
035   $a(EXLCZ)992550000001041251
100   $a20090330d2009      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aMolecular therapy of breast cancer$b[electronic resource] $eclassicism meets modernity /$fMarc Lacroix
210   $aNew York $cNova Biomedical Books$dc2009
215   $a1 online resource (303 p.)
225 1 $aCancer etiology, diagnosis and treatments series
300   $aDescription based upon print version of record.
311   $a1-60741-593-3 
320   $aIncludes bibliographical references and index.
327   $a""Molecular Therapy of Breast Cancer: Classicism Meets Modernity""; ""Dedication""; ""Contents ""; ""Preface""; ""Introduction ""; ""References ""; ""Selective Estrogen Receptor Modulators (SERMs) and Down-Regulators (SERDs)""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Selective Estrogen Receptor Modifiers (SERMs) ""; ""Tamoxifen ""; ""Toremifene ""; ""Fulvestrant ""; ""Conclusion ""; ""References ""; ""Aromatase Inhibitors ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Anastrozole ""; ""Letrozole ""; ""Exemestane ""
327   $a""Conclusion """"References ""; ""Agents Inducing Ovarian Suppression ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Goserelin ""; ""Triptorelin""; ""Leuprolide ""; ""Conclusion ""; ""References ""; ""Antimetabolites ""; ""Abstract ""; ""Introduction""; ""Clinical Trials in January 2009  ""; ""Fluorouracil ""; ""Capecitabine ""; ""Gemcitabine ""; ""Pemetrexed ""; ""Methotrexate ""; ""Conclusion ""; ""References""; ""Alkylating Agents ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Cyclophosphamide ""
327   $a""Platinum Compounds (Cisplatin, Carboplatin, Oxaliplatin, Picoplatin) - Generalities """"Cisplatin ""; ""Carboplatin ""; ""Oxaliplatin ""; ""Picoplatin ""; ""Temozolomide ""; ""Thiotepa""; ""Ifosfamide ""; ""Melphalan ""; ""Busulfan ""; ""Conclusion ""; ""References ""; ""Anthracyclines ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Doxorubicin ""; ""Liposomal Doxorubicin ""; ""Epirubicin ""; ""Conclusion ""; ""References""; ""Microtubule-Binding Agents ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Taxanes - Generalities ""
327   $a""Larotaxel """"Docetaxel ""; ""Paclitaxel and Nab-Paclitaxel ""; ""Epothilones - Generalities ""; ""Ixabepilone ""; ""Patupilone ""; ""Sagopilone ""; ""Vinca Alkaloids - Generalities ""; ""Vinorelbine""; ""Vinflunine ""; ""Eribulin ""; ""Conclusion ""; ""References ""; ""Topoisomerase Inhibitors ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Irinotecan ""; ""Etoposide ""; ""Conclusion ""; ""References""; ""HER Family Inhibitors ""; ""Abstract""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Trastuzumab ""; ""Lapatinib ""; ""Gefitinib ""
327   $a""Erlotinib """"Pertuzumab ""; ""Cetuximab ""; ""Ertumaxomab ""; ""Neratinib ""; ""Trastuzumab-MCC-DM1 ""; ""BIBW 2992 ""; ""ARRY-334543 ""; ""Conclusion ""; ""References ""; ""Angiogenesis Inhibitors ""; ""Abstract""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Bevacizumab""; ""Sunitinib ""; ""Vandetanib ""; ""Pazopanib ""; ""Ramucirumab ""; ""ABT-869 ""; ""AV-951 ""; ""PTC299""; ""AMG 386 ""; ""Aflibercept ""; ""Conclusion""; ""References ""; ""Insulin-Like Growth Factor-I Receptor (IGF-1R) Inhibitors""; ""Abstract""; ""Introduction ""; ""Clinical Trials in January 2009""
327   $a""Cixutumumab""
410  0$aCancer etiology, diagnosis, and treatments.
606   $aBreast$xCancer$xMolecular aspects
606   $aAntineoplastic agents
615  0$aBreast$xCancer$xMolecular aspects.
615  0$aAntineoplastic agents.
676   $a362.196/99449
676   $a362.196/99449
700   $aLacroix$b Marc$f1963-$01492984
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910779516303321
996   $aMolecular therapy of breast cancer$93846114
997   $aUNINA